Hemispherx Biopharma Inc.
One Penn Center
1617 JFK Boulevard
Philadelphia
Pennsylvania
19103
United States
Tel: 215-988-0080
Fax: 215-988-1739
Website: http://www.hemispherx.net/
350 articles about Hemispherx Biopharma Inc.
-
Hemispherx’s Ampligen Highlighted in Review of Role of TLR3 Agonist Support for “Universal” Flu Immunization Development Programs
1/31/2018
The first of the studies was in rodents, next in non-human primates (monkeys), and the third in healthy human subjects.
-
Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection
1/26/2018
Data will be reviewed on January 30, 2018 at the Keystone Symposia Conference on Emerging Technologies in Vaccine Discovery and Development.
-
Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes With Checkpoint Inhibitors
1/25/2018
Pawel Kalinski, MD presented data yesterday detailing the role of combination Ampligen therapy in making the microenvironment of solid tumors more responsive to immuno-oncology agents such as checkpoint inhibitors.
-
Hemispherx Comments on $500M+ Market Opportunity for Ampligen, the Only Late Stage ME/CFS Candidate in the U.S.
1/23/2018
Ampligen has orphan drug status in the U.S. for treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
-
Hemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production Facility
1/17/2018
Transaction helps boost Ampligen production to maximum levels.
-
Hemispherx Enhances Manufacturing Efficiency of Ampligen
1/11/2018
The manufacture of Ampligen, a double-stranded RNA, requires an enzyme which historically has been difficult to prepare.
-
Hemispherx Highlights Year-to-Date Progress, Outlines Key Objectives
12/19/2017
Hemispherx Biopharma announced the posting of a letter to shareholders on its website, www.hemispherx.com, in which CEO Thomas K. Equels reviews corporate activities progress over the past nine months and outlines key objectives going forward.
-
Hemispherx Biopharma CEO Interviewed on CEOLIVE.TV
11/15/2017
The interview can be viewed at: http://ceolive.tv/hemispherx-heb-ramping-up-manufacturing-to-pursue-multi-billion-dollar-immuno-oncology-market/.
-
Hemispherx Announces Corporate Progress And Financial Results For The Six Months Ended June 30, 2017
8/15/2017
-
Hemispherx Announces Corporate Progress And Financial Results For The Six Months Ended June 30, 2017
8/15/2017
-
Hemispherx To Host Conference Call To Discuss Second Quarter Financial Results On Tuesday, August 15, 2017
8/14/2017
-
Hemispherx Human Safety Study Of Intranasal Ampligen With Influenza Vaccine Shows Ampligen Was Generally Well-Tolerated
8/14/2017
-
Hemispherx Human Safety Study Of Intranasal Ampligen With Influenza Vaccine Shows Ampligen Was Generally Well-Tolerated
8/14/2017
-
Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer
7/10/2017
-
Hemispherx Repurposes Ampligen In Immuno-Oncology
6/1/2017
-
Hemispherx Enhances Ampligen Manufacturing And Scientific Capabilities
6/1/2017
-
Hemispherx Announces Financial Results For The Three Months Ended March 31, 2017
5/16/2017
-
Hemispherx Announces Financial Results For The Year Ended December 31, 2016
4/3/2017
-
Hemispherx Announces Conference Call Regarding Financial Results For The Year Ended December 31, 2016
4/3/2017
-
Hemispherx Meets Ampligen Sales Milestone In The 1st Quarter Of 2017
3/6/2017